Home › Funds › Redmile Group, LLC › AGMB
Redmile Group, LLC position in AGMB
AGOMAB THERAPEUTICS NV · Health Care
Redmile Group, LLC reported holding 2,733,926 shares of AGMB (AGOMAB THERAPEUTICS NV) in its Q2 2026 13F filing — a position valued at US$35.5M, representing 2.38% of its reported portfolio and ranking #12 among its reported holdings. Redmile Group, LLC has disclosed AGMB holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Redmile Group, LLC's AGMB position evolved
Redmile Group, LLC first disclosed a stake in AGMB in Q1 2026 at 156,250 shares (US$1.6M). The position peaked in Q2 2026 at 2,733,926 shares, worth US$35.5M. Across 2 filings, Redmile Group, LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 2,733,926 shares valued at US$35.5M — an increase of 2,577,676 shares quarter over quarter.. Notable position changes include a 1650% increase in Q2 2026 (shares fell 14% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 156.25K | $1.64M | New |
| Q2 2026 | 2.73M | $35.49M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AGMB and 13F data
AGMB (AGOMAB THERAPEUTICS NV) is a Health Care company. 33 other funds we track also report a position in AGMB — the largest reported positions include EQT Fund Management S.a r.l. (US$66.7M), Sanofi (US$36.1M), Cormorant Asset Management, LP (US$32.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AGMB
- EQT Fund Management S.a r.l. 5.14M sh · $66.74M · Q2 2026
- Sanofi 2.78M sh · $36.12M · Q2 2026
- Cormorant Asset Management, LP 2.47M sh · $32.00M · Q2 2026
- TCG Crossover Management, LLC 2.05M sh · $26.65M · Q2 2026
- Nantahala Capital Management, LLC 1.57M sh · $20.36M · Q2 2026
- Casdin Capital 1.55M sh · $20.12M · Q2 2026
- Andera Partners 1.54M sh · $17.08M · Q3 2026
- Samsara BioCapital, LLC 600.00K sh · $7.79M · Q2 2026
- PFIZER INC 75.00K sh · $1.04M · Q2 2026
More on Redmile Group, LLC
FAQ
How long has Redmile Group, LLC held AGMB?
Redmile Group, LLC has disclosed AGMB holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is Redmile Group, LLC's current position in AGMB?
As of Q2 2026, Redmile Group, LLC holds 2.73M shares of AGMB (AGOMAB THERAPEUTICS NV), valued at $35.49M, representing 2.38% of its reported portfolio and ranking #12.
Has Redmile Group, LLC been buying or selling AGMB?
In the latest 13F filing (Q2 2026), Redmile Group, LLC increased its position in AGMB. The position peaked in Q2 2026 at 2.73M shares.
Which other funds hold AGMB?
Other major institutional holders of AGMB include EQT Fund Management S.a r.l., Sanofi, Cormorant Asset Management, LP, among 33 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.